Skip to main content
. 2018 Jan 27;29(3):578–587. doi: 10.1093/annonc/mdy019

Figure 2.

Figure 2.

Incidence of TEAEs resulting in treatment discontinuation in ≥1% of patients in years 1, 2, 3, and 4 by cohort. CP 2L, chronic phase, second-line treatment; CP 3L, chronic phase, third-line treatment; TEAE, treatment-emergent adverse event. Denominators are the number of patients on treatment during the specific years.